Hepatitis C News

July 28 is World Hepatitis Day, and this year’s theme, “I can’t wait,” emphasizes the importance of testing and treatment and the need for greater global response to viral hepatitis elimination efforts.

In a Healio video exclusive, Harvey Kaufman, MD, senior medical director at Quest Diagnostics, highlighted the need for concurrent hepatitis B and latent tuberculosis testing to mitigate the risk for drug-induced liver injury.

Healio presents the top peer-tested articles from June, which include updates on the acute hepatitis outbreak in children, FDA approval of Skyrizi for Crohn’s disease, investigational care of patients with chronic constipation and more.

Individuals born in the United States made up nearly two-thirds of all hepatitis B-listed deaths, with death rates exceeding the national average in 13 states, according to research published in JAMA Network Open.

LONDON —Although progress has been made, nearly 12 million individuals will die early from preventable hepatitis B and hepatitis C deaths without additional interventions, according to research presented at the International Liver Congress.

LONDON — Noninvasive testing may predict clinically significant portal hypertension and other outcomes in patients after hepatitis C virus cure, according to research presented at the International Liver Congress.

LONDON — Lower MELD score predicted short- and long-term survival in patients with severe alcohol-associated hepatitis who were declined for early liver transplantation, according to research presented at the International Liver Congress.

LONDON — Direct-acting antiviral treatment correlated with a decreased risk for cardiovascular outcomes among patients with hepatitis C virus and advanced fibrosis but an increased risk for arrhythmias and conduction disorders.

LONDON — Nonalcoholic fatty liver disease and alcohol-associated liver disease are among the main contributors of increased mortality related to chronic liver disease and liver cancer burden, according to research.

LONDON — A high intensity test and treat initiative for hepatitis C elimination in England proved to be beneficial for testing and treating incarcerated individuals, according to results at the International Liver Congress.